Inovio Wins FDA Accelerated Approval for VOCERYQ
Inovio received FDA accelerated approval for VOCERYQ to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis.
Inovio received FDA accelerated approval for VOCERYQ to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis.Key Highlights:Original SEC Filing: INOVIO PHARMACEUTICALS, INC. [ INO ] - 8-K - Nov. 02, 2026This is an AI-powered summary. It may contain inaccuracies.
Consi…